TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin Monotherapy in Treatment-Refractory Germ Cell Tumors at the ESMO Congress 2026
Objective response rate of 45.5% and disease control rate of 72.7% observed in 11 heavily pretreated patients with recurrent germ cell tumors Responses observed in three of six patients with disease progression after high-dose chemotherapy and autologous stem cell transplantation, a...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


